Fortress Biotech, Inc. FBIO
2.28
0.00
0.00%
as of 25 Sep
- Market cap
- $76.0M
- P/E
- 0.7×
Follow FBIO
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.94 | 0.73 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
1.42 | 1.33 | 1.61 | 1.62 | |
P/FCF ratio |
1.13 | 0.74 | 0.00 | 0.00 | |
P/Operating CF |
(1.64) | 0.43 | (8.14) | (16.50) | |
P/B ratio |
0.47 | 0.43 | 1.64 | 1.55 | |
Price to Tangible BV |
0.54 | 0.50 | 2.95 | 2.76 | |
EV/Sales |
(0.89) | (1.92) | 1.25 | 1.06 | |
EV/EBITDA |
3.00 | 2.74 | 0.00 | 0.00 | |
EV/Operating CF |
(0.48) | (0.81) | (1.20) | (1.00) | |
EV/FCF |
(0.71) | (1.07) | (0.75) | (0.63) | |
Quick Ratio |
3.76 | 2.72 | 2.20 | 1.93 | |
Current Ratio |
3.96 | 2.86 | 2.49 | 2.19 | |
Net Debt/EBITDA |
19.62 | 47.76 | 10.18 | 7.94 | |
Debt/Assets |
10.93% | 10.33% | 28.25% | 26.34% | |
Debt/Equity |
0.17 | 0.18 | 0.84 | 0.73 | |
Asset Turnover |
0.29 | 0.25 | 0.38 | 0.40 | |
Operating CF/Net income |
23.94 | 1.88 | 2.02 | (1.66) | |
Capex/Depreciation |
(0.05) | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4.30% | 3.37% | (2.31%) | 1.18% | |
Selling, General and Administrative Expense of Revenue |
111.16% | 99.10% | 90.58% | 98.77% | |
Intangible Assets out of Total Assets |
0.08 | 0.07 | 0.15 | 0.16 | |
Share Based Compensation of Revenue |
15.78% | 10.48% | 15.29% | 18.14% | |
Graham Net Nets |
1.39 | 1.60 | 0.00 | 0.02 | |
Graham Number |
21.81 | 23.54 | 0.00 | 0.00 | |
Earnings Yield |
106.54% | 137.63% | (2.19%) | (12.45%) | |
Free Cash Flow Yield |
88.24% | 135.00% | (102.44%) | (104.20%) | |
Revenue per Share |
0.59 | 0.51 | 0.58 | 0.65 | |
Operating CF per Share |
(1.86) | 6.46 | (0.45) | (0.22) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.87) | 6.46 | (0.45) | (0.22) | |
Cash per Share |
6.18 | 8.11 | 2.85 | 3.16 | |
Shareholders Equity per Share |
6.48 | 6.42 | 2.23 | 2.39 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.48 | 6.42 | 2.23 | 2.39 | |
Free Cash Flow |
(59.36) | 203.85 | (12.54) | (6.11) | |
Working Capital |
183.49 | 192.09 | 74.10 | 64.44 | |
Capital Expenditures |
(0.08) | — | 0.00 | 0.00 | |
Net Current Asset Value |
134.88 | 140.98 | 0.48 | 2.28 | |
EV/EBIT |
2.09 | 2.29 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
(13.23%) | 675.68% | (38.54%) | 20.84% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
26.48 | 21.92 | 20.17 | 14.49 | |
Average Payables |
48.95 | 79.64 | 56.31 | 54.84 | |
Average Inventory |
10.50 | 10.89 | 12.03 | 11.80 | |
Average Assets |
238.31 | 267.47 | 164.89 | 154.25 | |
Average Common Equity |
121.73 | 117.43 | 30.27 | 26.22 |
Columns are period end dates